Wells Fargo & Company MN Purchases 6,622 Shares of Menlo Therapeutics Inc (NASDAQ:MNLO)

Share on StockTwits

Wells Fargo & Company MN increased its position in shares of Menlo Therapeutics Inc (NASDAQ:MNLO) by 28.2% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 30,136 shares of the company’s stock after purchasing an additional 6,622 shares during the quarter. Wells Fargo & Company MN’s holdings in Menlo Therapeutics were worth $180,000 at the end of the most recent reporting period.

Separately, Acadian Asset Management LLC lifted its position in Menlo Therapeutics by 18.0% during the first quarter. Acadian Asset Management LLC now owns 42,314 shares of the company’s stock worth $333,000 after purchasing an additional 6,459 shares during the period. 76.54% of the stock is owned by institutional investors and hedge funds.

Several equities research analysts recently weighed in on the stock. Zacks Investment Research cut shares of Menlo Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, July 3rd. ValuEngine raised shares of Menlo Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st.

MNLO opened at $4.74 on Friday. Menlo Therapeutics Inc has a twelve month low of $2.69 and a twelve month high of $9.03. The company has a 50-day simple moving average of $4.78 and a 200 day simple moving average of $5.69.

Menlo Therapeutics (NASDAQ:MNLO) last posted its quarterly earnings data on Thursday, August 1st. The company reported ($0.69) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.84) by $0.15. As a group, analysts anticipate that Menlo Therapeutics Inc will post -3.1 EPS for the current fiscal year.

Menlo Therapeutics Profile

Menlo Therapeutics Inc, a late-stage biopharmaceutical company, focuses on the development and commercialization of serlopitant for the treatment of pruritus associated with dermatologic conditions in the United States. The company has completed Phase II clinical trials in pruritus associated with prurigo nodularis; psoriasis; chronic pruritus; atopic dermatitis; and refractory chronic cough.

Featured Article: Calculating net profit and net profit margin ratio

Want to see what other hedge funds are holding MNLO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Menlo Therapeutics Inc (NASDAQ:MNLO).

Institutional Ownership by Quarter for Menlo Therapeutics (NASDAQ:MNLO)

Receive News & Ratings for Menlo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Menlo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.